Price
No data yet.
Social Signal Score
Revenue
$383.54M+74.12%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel Bendheim
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 2,475
- Beta
- 0.46
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.07
Financials
Revenue
$383.54M+74.1%Net Income
$24.02M+40.3%EBITDA
$55.64M+106.1%Free Cash Flow
$890.0KEPS (diluted)
$0.59+40.5%Shares Outstanding (diluted)
41.04M+1.3%Operating Expenses
$76.90MCash & Debt
$77.45MReturn of Capital
$4.87MRevenue by Segment (annual)
$137.15MDividend per Share
$0.12Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.30B | $48.26M | $1.19 |
| 2024 | $1.02B | $2.42M | $0.06 |
| 2023 | $977.89M | $32.61M | $0.81 |
| 2022 | $942.26M | $49.17M | $1.21 |
| 2021 | $833.35M | $54.38M | $1.34 |
| 2020 | $800.35M | $33.55M | $0.83 |
| 2019 | $828.00M | $54.70M | $1.35 |
| 2018 | $820.00M | $64.90M | $1.61 |
| 2017 | $764.30M | $64.60M | $1.63 |
| 2016 | $751.50M | $82.70M | $2.11 |
| 2015 | $748.59M | $60.28M | $1.55 |
| 2014 | $691.90M | $-3.10M | $-0.10 |
| 2013 | $653.15M | $24.89M | $0.82 |
| 2012 | $654.10M | $6.98M | $0.23 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from PAHC's reported EPS growth of 13.5% a year over 13 years.
- EPS in 5 years
- $2.24
- Implied price
- $47.14
- Return from $35.44
- 5.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $23.44 — -33.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 15 | 18 | 21 | 24 | 27 |
|---|---|---|---|---|---|
| 3.5% | -9.7% | -6.4% | -3.5% | -0.8% | 1.5% |
| 8.5% | -5.4% | -1.9% | 1.2% | 3.9% | 6.4% |
| 13.5% | -1.0% | 2.7% | 5.9% | 8.7% | 11.3% |
| 18.5% | 3.3% | 7.2% | 10.5% | 13.5% | 16.2% |
| 23.5% | 7.7% | 11.7% | 15.2% | 18.3% | 21.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsbusinesswire.com·6h ago·Neutral
…poration to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2026 financial results on Wednesday, August 26, 2026, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 27, 2026, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the pres…
View source ↗
Earnings
Wed, Aug 26(in 6 days)
Consensus estimate $0.72 per share
Typical surprise +23.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, May 6$0.76 vs $0.72beat
- Wed, Feb 4$0.87 vs $0.69beat
- Wed, Nov 5$0.73 vs $0.59beat
- Wed, Aug 27$0.57 vs $0.52beat
- Wed, May 7$0.63 vs $0.52beat
- Wed, Feb 5$0.54 vs $0.40beat
Estimates and results for PAHC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PAHC officers and directors.
- Bought
- $318k
- Sold
- $20.6m
1 trade
71 trades
- Corcoran E Thomasbought
- Bendheim Jacksold
- Bendheim Jacksold
- Bendheim Jacksold
- Bendheim Jacksold
- Bendheim Jacksold
- Bendheim Jacksold
- Bendheim Jacksold
28 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.